Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment 

Published by옥빈 준 Modified over 5 years ago

Similar presentations

Presentation on theme: "P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment "— Presentation transcript:

1 P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment  Roy S. Herbst, Paul Baas, Jose L. Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon  Journal of Thoracic Oncology  Volume 11, Issue 10, Pages S242-S243 (October 2016) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2016 11, S242-S243DOI: (10. 1016/j. jtho
Copyright © Terms and Conditions

Download ppt "P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment "

Similar presentations

P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC) 

P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC) 
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)

Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,

P3.02b-001 Phase 1 Dose Escalation of PF (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,
P1.08-044 Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.

P Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.
Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)

Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,

P Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,
P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,
MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging  Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,

MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging  Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,
PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis  Hyun Koo.

PUB023 Effectiveness of Three-Dimensional Video System in Single Port Thorascopic Major Pulmonary Resection: Propensity Score Matched Analysis  Hyun Koo.
P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)  Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.

P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)  Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Confessions of a journal junkie

Confessions of a journal junkie

Similar presentations

Ads by Google